Follow-up: IMI Unveils First Call

Europe's Innovative Medicines Initiative has unveiled details of the first 18 projects it will fund under a 5-year, 2 billion ($3.1 billion) program to relieve bottlenecks in drug discovery and development. In addition to programs focusing on safety prediction, pharmacovigilance, and education and training, the first-call projects include a trio of therapeutic areas: brain disorders, metabolic disease and pulmonary inflammatory indications.

As initially reported in SciBX, the first-call projects will receive up to 122.7 million ($189.2 million) from the EU to support research activities and an estimated in-kind contribution of 172.5 million ($266 million) from participating members of the European Federation of Pharmaceutical Industries and Associations (EFPIA).¹...